Advertisement
Advertisement
Eric Ng
News Editor, Climate
Eric joined the Post in 1998 after brief stints in a trading company, and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has over 20 years of experience covering China's energy, mining and industrial materials sectors, and has reported on China's healthcare and biotechnology sectors for three years. Currently, he leads the Post's coverage on climate change, energy transition and sustainability topics. Eric has a Masters of Business Administration degree.
Eric joined the Post in 1998 after brief stints in a trading company, and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has over 20 years of experience covering China's energy, mining and industrial materials sectors, and has reported on China's healthcare and biotechnology sectors for three years. Currently, he leads the Post's coverage on climate change, energy transition and sustainability topics. Eric has a Masters of Business Administration degree.
Areas of Expertise:
Energy, industrial materials, biotechnology Languages Spoken:
English, Mandarin, Cantonese
Achelous Pure Metals plans to bring its scalable, movable, eco-friendly technology to the city followed by Southeast Asia.
FDA says a ‘statistically significant’ benefit on overall survival is required to approve the ivonescimab antibody.
Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.
Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.
Advertisement
Company aims to raise US$70 million to develop its systems, which it claims rival the market-leading da Vinci units at lower cost.
City will support tech start-ups with long-term investments and strategic partnerships, Chan says.
Company also aiming for a Hong Kong listing in one to two years, chief financial officer says.
The fund’s manager expects gold to hit US$4,000 this year due to a weakening US dollar and rising demand from investors.
Company says its test is the world’s first urine-based screening for the virus that causes 95 per cent of cervical cancer cases.
Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley says.
Trump seeks to slash domestic drug prices, bring back pharmaceutical manufacturing to the US and slap tariffs on imports.
Chinese dominance of shipbuilding is a ‘reality’ that will not change no matter what fees the US applies, Guy Platten says.
Industry ‘in an absolute panic’ since February when China cut off exports now recognises need to diversify sources, Almonty CEO says.
China’s Hengrui Pharmaceuticals seeks a path to growth as its pipeline of novel drugs expands.
Pharus Diagnostics, backed by Li Ka-shing, seeks Hong Kong funds for AI-driven cancer tests.
Company raised US$20 million of fresh capital last month from investors including existing backer Lilly Asia Ventures.
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.
Chinese firms have been exporting from offshore factories to beat US tariffs for a decade, and Washington is determined to shut the loophole.
State-backed energy firms and private distributors may have to renegotiate long-term liquefied-natural-gas contracts, analysts say.
Foresight in building offshore factories to benefit Qingdao Sentury, Sailun Group as exporters navigate higher US tariffs on auto parts.
Xpeng’s Turing AI chip is three times more powerful in computing power than the Nvidia chip installed in its existing EVs.
Blood-cancer medicine, manufactured in the US, won conditional approval for sale in mainland China last month.
With biotech firms caught in the crosshairs of Trump’s tariffs, the levy could prove to be a boon for domestic producers but a bane for exporters.
Treatment uses electric pulses to kill prostate cancer cells while minimising risks of incontinence and sexual dysfunction.
Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.
Chinese company says DeepSeek’s AI model will enhance data mining in its platform, delivering efficiency to hospitals and pharmacies.
Natixis says China’s power-equipment industry needs to shift its investment focus to storage and distribution infrastructure.
A pilot programme in Shenzhen showed that trucks that run on batteries beat diesel-fuelled vehicles in terms of total cost of ownership.
ATRenew, China’s largest platform for pre-owned electronics, is offering trade-in incentives to coincide with the Lunar New Year holiday.
